{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266959","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.719204+00:00","generated_at":"2026-05-17T00:10:03.911301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance","bullets":["Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).","Q3 net income $71.8M ($0.42 diluted EPS) vs. $32.8M ($0.20) in Q3 2024.","Full-year 2025 total revenue guidance raised to $1.07-1.095B from $1.045-1.095B.","NUPLAZID guidance raised to $685-695M; DAYBUE guidance tightened to $385-400M.","Cash & investments $847M at Sept 30, 2025 vs. $756M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266959","json":"https://secwatch.observer/filing/0001193125-25-266959.json","markdown":"https://secwatch.observer/filing/0001193125-25-266959.md","text":"https://secwatch.observer/filing/0001193125-25-266959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/0001193125-25-266959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/acad-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:10:03.911301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}